News

SEATTLE, Aug. 8, 2013 /PRNewswire/ — Cardinal Health today launched the Specialty Pharmacy Alliance, a new suite of services that make it easier for community pharmacies to improve their patients’ access to and compliance with specialty medications, which usually require specialized handling, dispensing, administration and patient counseling services. These medications are often high-cost and high-touch, […]

August 08, 2013 – Sandoz is excited to announce the re-launch of our biosimilars website, Sandoz-Biosimilars.com Sandoz is excited to announce the re-launch of our biosimilars website, Sandoz-Biosimilars.com . The site is a comprehensive educational resource, designed for visitors with varying levels of knowledge, that explains what biosimilars are, their importance, and how they are developed […]

SEATTLE, Aug. 7, 2013 /PRNewswire/ — Thousands of independent pharmacists will converge in Seattle for Cardinal Health’s annual Retail Business Conference August 7-10. This year’s event encourages independent pharmacies to Discover New Horizons for improving their businesses and for delivering quality, personalized care to patients. The tradeshow features a 95,000-square-foot trade exhibit floor, highlighting buying […]

Dublin, Ohio, July 26, 2013 — Cardinal Health executives will highlight forward-thinking supply chain solutions for the evolving healthcare landscape at the Association for Healthcare Resource and Materials Management (AHRMM) annual conference in San Diego July 28 – 31. Steve Inacker, president, Hospital Sales and Services at Cardinal Health will co-present at one of the conference’s […]

Holzkirchen, Germany, July 22, 2013 – Sandoz, the global leader in biosimilars, is pleased that Zarzio® (filgrastim) has become the first biosimilar to overtake both its reference product (Amgen’s Neupogen®) and European market leader (Chugai’s Granocyte®) and is now the most prescribed daily G-CSF in Europe and the #1 biosimilar daily G-CSF globally. The success of Zarzio […]

Princeton, New Jersey , July 02, 2013 – Sandoz today announced the US launch of metronidazole 1% topical gel, the first generic version of METROGEL® 1%. Metronidazole 1% topical gel is indicated for the topical treatment of inflammatory lesions of rosacea1, a condition that affects an estimated 16 million Americans.2 “This significant launch further expands our […]

– Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose – Exelon Patch first and only transdermal therapy approved to treat all stages of Alzheimer’s – More than five million Americans are living with […]

New Tulsa Cancer Institute Offers Accuray’s Latest Cancer Fighting Technology SUNNYVALE, Calif., June 25, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today that the Tulsa Cancer Institute is the first U.S. center to treat a patient with Accuray’s TomoHDA™ System, the latest and most advanced innovation in the TomoTherapy® product lineage designed to treat the full spectrum of cancer […]

Holzkirchen, Germany,   June 24, 2013 – Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen’s Enbrel®). Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global […]

Tokyo, Japan, June 21, 2013 – Sandoz today announces the National Health Insurance price listing and launch in Japan of sodium risedronate tablets 2.5mg/17.5 mg [Sandoz], the generic version of BENET® Tablets / ACTONEL® Tab. Sodium risedronate tablets 2.5mg/17.5 mg are indicated for the treatment of osteoporosis. “Sandoz is proud to launch this important generic medicine, […]